<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2014-17-42-49</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>Особенности антигипертензивной терапии при ожирении</article-title><trans-title-group xml:lang="en"><trans-title>Antihypertensive therapy in obesity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Недогода</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nedogoda</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саласюк</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Salasyuk</surname><given-names>A. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барыкина</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Barykina</surname><given-names>I. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цома</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsoma</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чумачек</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chumachek</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хрипаева</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Khripaeva</surname><given-names>V. Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2014</year></pub-date><volume>0</volume><issue>17</issue><fpage>42</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Недогода С.В., Саласюк А.С., Барыкина И.Н., Цома В.В., Чумачек Е.В., Хрипаева В.Ю., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Недогода С.В., Саласюк А.С., Барыкина И.Н., Цома В.В., Чумачек Е.В., Хрипаева В.Ю.</copyright-holder><copyright-holder xml:lang="en">Nedogoda S.V., Salasyuk A.S., Barykina I.N., Tsoma V.V., Chumachek E.V., Khripaeva V.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/773">https://www.med-sovet.pro/jour/article/view/773</self-uri><abstract><p>В настоящее время ожирение является одной из наиболее важных междисциплинарных медицинских проблем. Оно является одной из основных причин повышения АД. Так, по данным Фраменгемского исследования, ожирение вероятно играет основную роль в развитии гипертонической болезни у 78% мужчин и 65% женщин [<xref ref-type="bibr" rid="cit10">10</xref>]. При этом сами жировые клетки играют важную роль в развитии артериальной гипертензии, т. к. продуцируют самые различные биологически активные субстанции, часть из которых обладает прессорными и провоспалительными эффектами. Особенно важным в этом плане является лептин, который посредством активации симпатической нервной системы и прямого действия на почки (усиление реабсорбции натрия) способствует повышению АД. Кроме этого, ожирение само по себе негативно влияет на структуру почечной ткани и повышает риск развития почечной недостаточности и прогрессирования артериальной гипертензии. Также жировая ткань, обладая собственной ренин-ангиотензиновой системой, может активно продуцировать ангиотензин.</p></abstract><trans-abstract xml:lang="en"><p>Obesity today is one of the most relevant interdisciplinary problems in healthcare and one of the key reasons for blood pressure increase. Thus, according to the Framingham Heart Study,78% of hypertension in men and 65% in women can be directly attributed to obesity [<xref ref-type="bibr" rid="cit10">10</xref>]. Fat cells play an important role in the development of hypertension, i.e. they generate a variety of biologically active substances some of which have pressor and proinflammatory effects. Leptin is one of key substances which contributes to the increase of AP through the activation of the sympathetic nervous system and direct effect on kidneys (increased sodium reabsorption). Furthermore, obesity itself adversely affects the structure of renal tissue and increases the risk of progression of renal failure and hypertension. In addition, fatty tissue has its own renin-angiotensin system and may actively produce angiotensin.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>антигипертензивная терапия</kwd><kwd>ренин-ангиотензиновая система</kwd><kwd>периндоприл</kwd><kwd>obesity</kwd><kwd>antihypertensive therapy</kwd><kwd>renin-angiotensin system</kwd><kwd>perindopril</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В. Ожирение и артериальная гипертензия: теория и практика выбора оптимального гипотензивного препарата. М.: Медиком, 2012. С. 1-80.</mixed-citation><mixed-citation xml:lang="en">Недогода С.В. Ожирение и артериальная гипертензия: теория и практика выбора оптимального гипотензивного препарата. М.: Медиком, 2012. С. 1-80.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bergman RN, Van Otters GW, Mittelman SD et al. Central role of adipocyte in the metabolic syndrome. J Invest Med, 2001, 49: 119-126.</mixed-citation><mixed-citation xml:lang="en">Bergman RN, Van Otters GW, Mittelman SD et al. Central role of adipocyte in the metabolic syndrome. J Invest Med, 2001, 49: 119-126.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chu NF, Spiegelman D, Hotamisligil GS et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease factors among men. Atherosclerosis, 2001, 157: 495-503.</mixed-citation><mixed-citation xml:lang="en">Chu NF, Spiegelman D, Hotamisligil GS et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease factors among men. Atherosclerosis, 2001, 157: 495-503.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and cause of death in morbidly obese men.JAMA, 1980, 243: 443-445.</mixed-citation><mixed-citation xml:lang="en">Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and cause of death in morbidly obese men.JAMA, 1980, 243: 443-445.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Esler M The sympathetic system and hypertension. Am JHypertens, 2000, 13: 99S-105S.</mixed-citation><mixed-citation xml:lang="en">Esler M The sympathetic system and hypertension. Am JHypertens, 2000, 13: 99S-105S.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gorzelniak K, Engeli S, Janke J et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens, 2002, 20: 1115-1120.</mixed-citation><mixed-citation xml:lang="en">Gorzelniak K, Engeli S, Janke J et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens, 2002, 20: 1115-1120.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension,1992, 19 (suppl. 1): I78-I82.</mixed-citation><mixed-citation xml:lang="en">Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension,1992, 19 (suppl. 1): I78-I82.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens, 1997, 10: 49S-55S.</mixed-citation><mixed-citation xml:lang="en">Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens, 1997, 10: 49S-55S.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension, 2001, 37: 670-676.</mixed-citation><mixed-citation xml:lang="en">Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension, 2001, 37: 670-676.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Licata G, Scaglione, Capuana G, Parrinello G, Divincenzo D, Mazzola G. Hypertension in obese subjects: distinct hypertensive subgroup. J Hum Hypertens, 1990, 4: 37-41.</mixed-citation><mixed-citation xml:lang="en">Licata G, Scaglione, Capuana G, Parrinello G, Divincenzo D, Mazzola G. Hypertension in obese subjects: distinct hypertensive subgroup. J Hum Hypertens, 1990, 4: 37-41.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Laasko M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J Clin Invest, 1990, 85: 1844-1852.</mixed-citation><mixed-citation xml:lang="en">Laasko M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J Clin Invest, 1990, 85: 1844-1852.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mansuo K, Mikami H, Ogihara T, Tuck ML 2000 Weight gain-induced blood pressure elevation. Hypertension, 35: 1135-1140.</mixed-citation><mixed-citation xml:lang="en">Mansuo K, Mikami H, Ogihara T, Tuck ML 2000 Weight gain-induced blood pressure elevation. Hypertension, 35: 1135-1140.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Messerli FH, Sundgard-Riiske K, Reisin E, Frohlich ED, Dunn FG. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med, 1998, 99: 757-761.</mixed-citation><mixed-citation xml:lang="en">Messerli FH, Sundgard-Riiske K, Reisin E, Frohlich ED, Dunn FG. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med, 1998, 99: 757-761.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nedogoda S et al. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension. Clin Drug Investig, 2013, 33: 553-561.</mixed-citation><mixed-citation xml:lang="en">Nedogoda S et al. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension. Clin Drug Investig, 2013, 33: 553-561.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-LaRocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens, 1999, 17: 1125-1133.</mixed-citation><mixed-citation xml:lang="en">Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-LaRocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens, 1999, 17: 1125-1133.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma AM, Pischon T, Engeli S et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens, 2001, 19: 667-674.</mixed-citation><mixed-citation xml:lang="en">Sharma AM, Pischon T, Engeli S et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens, 2001, 19: 667-674.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shek EW, Kim PK, Hall JE. Adrenergic blockade prevents leptin-induced hypertension. FASEB J, 1999, 13: A456.</mixed-citation><mixed-citation xml:lang="en">Shek EW, Kim PK, Hall JE. Adrenergic blockade prevents leptin-induced hypertension. FASEB J, 1999, 13: A456.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang R, Reisin E Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens, 2000, 13: 1308-1314.</mixed-citation><mixed-citation xml:lang="en">Zhang R, Reisin E Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens, 2000, 13: 1308-1314.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
